Here are four things to know:
1. The regulations stripped the tax benefits New York-based Pfizer sought from its merger with Allergan, based in Dublin, Ireland.
2. Allergan CEO Brent Saunders said the U.S. government set those regulations to block the deal, valued at $160 billion.
3. To save money in tax revenues, Pfizer recently moved its tax addresses to Dublin. Many political figures such as Hillary Clinton scorned the move.
4. The $160 billion deal is one of the largest deals between drug companies to date.
“For the rules to be changed after the game has started to be played is a bit un-American, but that’s the situation we’re in,” Mr. Saunders said.
More articles on quality & infection control:
Pfizer considers nixing $160B Allergan merger amidst new tax regulations — 3 insights
Time to break the silence — 4 notes on surgeons coping after an adverse event
Zika causes various neurological disorders: 4 observations
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
